

BioPharma

Latest Updates

Here are this week's BioPharma updates - **September 15th, 2025.**

Funding

- [Kriya Therapeutics](#) (NC, USA) raised \$320M in Series D funding to advance clinical trials for its gene therapy pipeline in chronic diseases including geographic atrophy, thyroid eye disease, type 1 diabetes, MASH, and trigeminal neuralgia, while expanding its integrated R&D and manufacturing platform.
- [Lila Sciences](#) (MA, USA) raised \$235M in Series A funding to expand its AI-driven platform that integrates generative models with autonomous labs for accelerating drug discovery and materials development, bringing the company to unicorn status.
- [Odyssey Therapeutics](#) (MA, USA) raised \$213M in oversubscribed Series D funding to advance its pipeline of clinical and preclinical medicines targeting autoimmune and inflammatory diseases.
- [NRG Therapeutics](#) (Stevenage, United Kingdom) raised \$67M in oversubscribed Series B funding to advance its lead program NRG5051 into clinical proof of concept for ALS/MND and generate early clinical data in Parkinson's disease.
- [CUTISS](#) (Zurich, Switzerland) raised \$63M in Series C funding to advance the Phase 3 trial and commercialization of its bio-engineered skin graft denovoSkin™, progress its automated tissue therapy platform, and prepare the launch of VitiCell®.
- [Epigenic Therapeutics](#) (Shanghai, China) raised \$60M in Series B funding to advance clinical development of its epigenetic therapies, including programs for chronic hepatitis B and hypercholesterolemia, while also progressing preclinical candidates and expanding its technology platforms.

- [YolTech Therapeutics](#) (Shanghai, China) raised \$45M in Series B funding to advance its in vivo genome editing programs, including therapies for ATTR, familial hypercholesterolemia, PH1, and TDT/SCD, and to expand global development efforts.
- [iRegene Therapeutics](#) (Chengdu, China) raised \$40M in Series B+ funding to advance global clinical development of its iPSC-derived cell therapy NouvNeu001 for Parkinson's disease and expand programs in retinal disorders.
- [SafeHeal](#) (Paris, France) raised \$11M in Series C extension funding to advance its pivotal U.S. trial and support the EU launch of Colovac®, a device designed to avoid temporary stomas in colorectal cancer surgery.
- [Madison Scientific](#) (IL, USA) raised \$10M in seed funding to advance development of its SmartShunt system, a smart electro-mechanical device designed to improve treatment and long-term care for patients with hydrocephalus and other neurologic conditions.
- [Cascade Bio](#) (CO, USA) raised \$6M, combining seed funding and NSF grants, to scale its enzyme-stabilizing biocatalyst platform that extends enzyme activity and enables cost-efficient biomanufacturing.
- [PeriVision](#) (Bern, Switzerland) raised \$3M in seed funding to expand its AI- and VR-based VisionOne platform for faster, more accessible eye disease diagnostics and to grow its international presence.
- [NanoNewron](#) (NJ, USA) received a \$2.5M NIH STTR Phase 2 grant to advance its NN-840 program for Alzheimer's disease, supporting IND-enabling studies ahead of a planned filing next year.
- [Inkocell Therapeutics](#) (Lausanne, Switzerland) received a \$168K grant from Venture Kick to advance its next-generation NK-tailored CAR cell therapy platform aimed at developing scalable, safer, and off-the-shelf treatments for cancer and other serious diseases.
- [Immix Biopharma](#) (CA, USA) received a strategic investment from Goose Capital to advance development of its lead CAR-T program NXC-201 for relapsed/refractory AL Amyloidosis and other serious diseases.
- [Valo Health](#) (MA, USA) received an undisclosed Michael J. Fox Foundation grant to investigate NOD2 as a Parkinson's target using human datasets and AI to determine optimal target modulation.
- [Dewpoint Therapeutics](#) (MA, USA) raised an undisclosed amount in Series D funding to advance its condensate modulator DPTX3186 into clinical trials for gastric cancer and accelerate development of additional c-mod programs.

Emerging

- [Ridge Biotechnologies](#) (CA, USA) emerged from stealth with \$25M in seed funding to develop AI-enabled precision enzyme and drug design platforms, supporting next-generation antibody conjugates and enzyme-based therapeutics.

Post IPO Equity

- [Avidity Biosciences](#) (CA, USA) announced an underwritten public offering of \$500M in common stock to advance late-stage clinical programs, expand commercial infrastructure, and support R&D and general corporate purposes.
- [Dianthus Therapeutics](#) (MA, USA) announced closing of a \$288M underwritten public offering to advance preclinical and clinical development activities as well as for working capital and general corporate purposes.
- [Rapport Therapeutics](#) (MA, USA) announced pricing of a \$250M underwritten public offering to advance its precision medicine pipeline for neurological and psychiatric disorders and for general corporate purposes.
- [Amylyx Pharmaceuticals](#) (MA, USA) announced pricing of a \$175M underwritten public offering to support Avexitide commercial readiness, research and development, working capital, and general corporate purposes.
- [Maze Therapeutics](#) (CA, USA) announced pricing of an oversubscribed \$150M private placement to advance kidney and metabolic disease programs, including MZE829 and MZE782, progress its Compass platform, and support general corporate purposes.
- [Belite Bio](#) (CA, USA) raised \$125M in a PIPE financing to support commercialization preparation, working capital, and general corporate purposes.
- [CAMP4 Therapeutics](#) (MA, USA) announced pricing of a private placement of ~\$100M to advance its SYNGAP1 program, fund R&D, and support working capital and general corporate purposes.
- [Lucid Diagnostics](#) (NY, USA) announced closing of a \$28.75M underwritten public offering to support working capital and general corporate purposes.
- [SELLAS Life Sciences](#) (NY, USA) announced the immediate exercise of warrants for \$23.6M in gross proceeds, with new warrants issued in a concurrent private placement.

- [Sirnaomics](#) (MD, USA) raised ~\$17.7M in a strategic investment from Bloomage Biotech to accelerate development and commercialization of its aesthetics and longevity RNAi pipeline, including the STP705 fat reduction program.
- [Actuate Therapeutics, Inc.](#) (TX, USA) announced closing of a \$17.25M underwritten public offering to support working capital and general corporate purposes, including a 30-day option for underwriters to purchase additional shares.
- [Talphera](#) (CA, USA) raised \$17M in a private placement led by CorMedix with the potential for an additional \$12M upon achieving the primary endpoint in the NEPHRO CRRT study, providing capital through the planned approval of Niyad in 2026.
- [Alterity Therapeutics](#) (Melbourne, Australia) announced pricing of a \$13.2M private placement to fund non-clinical studies, CMC activities, and clinical and regulatory development of ATH434 for Multiple System Atrophy, as well as for general working capital.
- [Xanadu Bio](#) (PA, USA) raised \$11M through a private stock sale to advance its PACE nanoparticle delivery platform and expand its pipeline of vaccines and tissue-targeted nucleic acid therapies.
- [Revelation Biosciences Inc.](#) (CA, USA) announced the immediate exercise of warrants for \$9.6M in gross proceeds at \$2.20 per share, with new Class I warrants issued in a concurrent private placement.
- [Beyond Air](#) (NY, USA) raised \$3.25M through the immediate exercise of outstanding warrants to advance clinical and pre-clinical programs, operating expenses, and working capital.
- [Hemostemix](#) (Calgary, Canada) raised \$280K through a non-brokered private placement to support general working capital, operational expenses, and business development activities.

Post IPO Debt

- [Alnylam Pharmaceuticals](#) (MA, USA) announced the commencement of a \$500M private offering of convertible senior notes to fund capped call transactions, repurchase a portion of its 2027 notes, and for general corporate purposes.
- [Celcuity](#) (MN, USA) announced an upsized senior secured credit facility of \$500M to support the rolling NDA submission and potential commercial launch of gedatolisib and other strategic initiatives.

- [Serina Therapeutics, Inc.](#) (AL, USA) secured up to \$20M in multi-tranche unsecured convertible note financing, with attached warrants, to support its Phase 1b registrational study of SER-252 in advanced Parkinson's disease.

Mergers and Acquisitions

- [GTCR](#) (IL, USA) to acquire [Zentiva](#) (Prague, Czech Republic) from [Advent International](#) for \$2.3B to strengthen its position in the European generics market.
- [Novartis](#) (Basel, Switzerland) to acquire [Tourmaline Bio](#) (NY, USA) for \$1.25B to strengthen its cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease.
- [Nestlé](#) (Vevey, Switzerland) to acquire [Seres Therapeutics](#) (MA, USA) for \$760M to expand its microbiome therapy portfolio.
- [Servier](#) (Suresnes, France) to acquire KER-0193 from [Kaerus Bioscience](#) (London, United Kingdom) for up to \$450M, to advance a potential oral small-molecule treatment for Fragile X syndrome, the most common single-gene cause of autism spectrum disorder.
- [Boston Scientific](#) (MA, USA) to acquire EluPro™ and CanGaroo® bioenvelopes from [Elutia](#) (MD, USA) for \$88M to expand its implantable device protection portfolio, while Elutia uses proceeds to fund development and commercialization of NXT-41 in breast reconstruction.
- [FOXO Technologies, Inc.](#) (FL, USA) to acquire [Vector Biosource](#) (MA, USA) ~\$6M in cash, preferred stock, and warrants, expanding its capabilities in biospecimen sourcing and healthcare data services.
- [GE Healthcare](#) (IL, USA) to acquire [Icometrix](#) (Leuven, Belgium) to integrate its AI-powered icobrain platform with GE's MRI systems, strengthening precision neurology solutions and advancing Alzheimer's disease care.

Partnerships

- [Samsung Biologics](#) (Incheon, South Korea) announced a \$1.3B contract manufacturing deal with an undisclosed U.S.-based pharmaceutical company running through 2029 to provide large-scale biologics production.
- [Xilio Therapeutics](#) (MA, USA) and [Gilead Sciences](#) (CA, USA) announced the initiation of a Phase 2 trial for efarindodekin alfa (XTX301) in advanced solid tumors and the achievement of a \$17.5M development milestone under their license agreement.

- [Remedium Bio](#) (MA, USA) and [Eli Lilly and Company](#) (IN, USA) announced a multi-target R&D collaboration to develop gene therapies for Type 2 diabetes and obesity using Remedium's Prometheus™ platform, with Remedium receiving upfront, equity, milestone payments, and royalties on sales.
- [AMO Pharma](#) (Leeds, United Kingdom) and [Population Health Research Institute](#) (Hamilton, Canada) announced a license agreement to advance AMO-02 for arrhythmogenic right ventricular cardiomyopathy, with a 120-patient Phase 2 proof-of-concept trial now underway across 17 sites in Canada.
- [KBI Biopharma](#) (NC, USA) and [Infinimmune](#) (CA, USA) announced a collaboration to advance manufacturing of IFX-101, Infinimmune's lead human monoclonal antibody for atopic dermatitis, leveraging KBI's SUREmAb™ platform and Infinimmune's GLIMPSE™ and Anthrobody® technologies.
- [Tolerance Bio](#) (PA, USA) and [ZipCode Bio](#) (MA, USA) announced a strategic R&D collaboration to develop thymus-targeting RNA therapeutics for immune aging and autoimmunity, combining ZipCode's SHARP delivery technology with Tolerance Bio's expertise in thymus biology.
- [Kytopen](#) (MA, USA) and [BlueWhale Bio](#) (PA, USA) announced a collaboration to develop a non-viral cell therapy manufacturing workflow combining Flowfect® and Synecta™ technologies to accelerate and scale personalized cell therapies.
- [VolitionRx](#) (NV, USA) and [Werfen](#) (Spain) announced a research license and exclusive commercial option agreement to evaluate and potentially commercialize the Nu.Q® NETs assay for Antiphospholipid Syndrome (APS).
- [Promega](#) (WI, USA) and [Watchmaker Genomics](#) (CO, USA) announced a strategic partnership to license a novel engineered reverse transcriptase to enhance RNA analysis accuracy and sensitivity for clinical, applied, and pharmaceutical applications.
- [Evonik](#) (Essen, Germany) and [Ethris](#) (Planegg, Germany) announced a strategic collaboration to develop and market a novel SNaP LNP® delivery platform, expanding Evonik's CDMO services and advancing RNA-based therapeutics and vaccines.
- [Circle Pharma, Inc.](#) (CA, USA) and [Eli Lilly and Company](#) (IN, USA) announced a collaboration enabling Circle to use Lilly's AI/ML TuneLab platform to advance its MXMO™ macrocycle drug discovery platform and oncology pipeline.
- [VedaBio](#) (CA, USA) and [Mammoth Biosciences](#) (CA, USA) announced a non-exclusive license agreement granting VedaBio access to CRISPR technologies to accelerate development of next-generation diagnostic solutions.

- [NeuraLight](#) (Tel Aviv, Israel) and [CHDI Foundation](#) (NY, USA) announced a collaboration to develop novel, sensitive biomarkers for Huntington's disease clinical trials using NeuraLight's eye movement data capture platform.
- [Scipher Medicine](#) (MA, USA) and Maxymune Therapeutics (CA, USA) announced a strategic collaboration to leverage Scipher's AI-driven precision immunology platform for target ranking and validation in autoimmune and inflammatory diseases.
- [Marius Pharmaceuticals](#) (NC, USA) and [Hims & Hers](#) (CA, USA) announced a collaboration to make KYZATREX®, the first FDA-approved oral testosterone therapy, available through the Hims & Hers digital health platform.
- [Ignite Proteomics](#) (CO, USA) and [Inova Health](#) (VA, USA) announced a research collaboration to apply Reverse Phase Protein Array technology in gastrointestinal cancers, enabling functional proteomics data to guide precision oncology treatment decisions.
- [Medicines Discovery Catapult](#) (United Kingdom) and [Crown Bioscience](#) (CA, USA) announced a strategic global collaboration to deliver an integrated translational biology platform for radiopharmaceutical development, combining radiochemistry, imaging, and preclinical oncology expertise to accelerate novel cancer therapies.
- [Kashiv BioSciences](#) (NJ, USA) and [CRISTÁLIA](#) (Sao Paulo, Brazil) announced a licensing and supply agreement for the commercialization of ADL-018, a proposed Xolair® biosimilar, across Latin America.
- [N-Power Medicine, Inc.](#) (CA, USA) and [VieCure](#) (CO, USA) announced a strategic partnership to integrate the Kaleido Registry™ with the Halo Intelligence Platform, expanding clinical trial access and precision medicine insights in community oncology practices.
- [Cellestar Biosciences](#) (NJ, USA) and [ITM Isotope Technologies Munich](#) (Germany) announced a supply agreement for Actinium-225 to support the clinical development of Cellestar's actinium-labeled radiopharmaceutical candidates, including CLR 121225 for solid tumors.
- [Recipharm](#) (Stockholm, Sweden) and [NeuroSense Therapeutics](#) (MA, USA) announced a partnership to develop and manufacture PrimeC, a fixed-dose ALS therapy, overcoming complex formulation challenges to support late-stage clinical trials and future commercialization.
- [INBRAIN Neuroelectronics](#) (Barcelona, Spain) and [Mayo Clinic](#) (NY, USA) announced a collaboration to accelerate clinical evaluation and commercialization of INBRAIN's graphene-based BCI-Tx platform for neurological disorders.

Initial Public Offering (IPO)

- [LB Pharmaceuticals](#) (NY, USA) announced pricing of its upsized \$285M initial public offering to advance development of its neuropsychiatric disease pipeline and support general corporate purposes.

Registered Direct Offering

- [Cocrystal Pharma, Inc.](#) (WA, USA) announced ~\$13M registered direct offering priced at-the-market under Nasdaq rules, including \$4.7M upfront and up to \$8.3M from warrant exercises, to support working capital and general corporate purposes.
- [Citius Oncology, Inc.](#) (NJ, USA) announced closing of a \$9M registered direct offering with concurrent private placement of warrants to support its oncology portfolio and general corporate purposes.

Closures and Layoffs

- [Lundbeck](#) (Copenhagen, Denmark) to lay off 602 employees as part of a resource reallocation strategy and exit from 27 markets.
- [Novo Nordisk](#) (Ballerup, Denmark) is laying off roughly 9,000 employees, including 5,000 in Denmark, to save around \$1.3 billion annually by the end of 2026.